> Details

Cherry, Allison E.; Haas, Brian R.; Naydenov, Alipi V.; Fung, Susan; Xu, Cong; Swinney, Katie; Wagenbach, Michael; Freeling, Jennifer; Canton, David A.; Coy, Jonathan; Horne, Eric A.; Rickman, Barry; Vicente, Juan Jesus; Scott, John D.; Ho, Rodney J.Y.; Liggitt, Denny; Wordeman, Linda; Stella, Nephi

ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme
  • Contributor: Cherry, Allison E.; Haas, Brian R.; Naydenov, Alipi V.; Fung, Susan; Xu, Cong; Swinney, Katie; Wagenbach, Michael; Freeling, Jennifer; Canton, David A.; Coy, Jonathan; Horne, Eric A.; Rickman, Barry; Vicente, Juan Jesus; Scott, John D.; Ho, Rodney J.Y.; Liggitt, Denny; Wordeman, Linda; Stella, Nephi
  • Published: American Association for Cancer Research (AACR), 2016
  • Published in: Molecular Cancer Therapeutics, 15 (2016) 9, Seite 2018-2029
  • Language: English
  • DOI: 10.1158/1535-7163.mct-15-0800
  • ISSN: 1535-7163; 1538-8514
  • Origination:
  • Footnote:
  • Description: Abstract Glioblastoma multiforme is a devastating and intractable type of cancer. Current antineoplastic drugs do not improve the median survival of patients diagnosed with glioblastoma multiforme beyond 14 to 15 months, in part because the blood–brain barrier is generally impermeable to many therapeutic agents. Drugs that target microtubules (MT) have shown remarkable efficacy in a variety of cancers, yet their use as glioblastoma multiforme treatments has also been hindered by the scarcity of brain-penetrant MT-targeting compounds. We have discovered a new alkylindole compound, ST-11, that acts directly on MTs and rapidly attenuates their rate of assembly. Accordingly, ST-11 arrests glioblastoma multiforme cells in prometaphase and triggers apoptosis. In vivo analyses reveal that unlike current antitubulin agents, ST-11 readily crosses the blood–brain barrier. Further investigation in a syngeneic orthotopic mouse model of glioblastoma multiforme shows that ST-11 activates caspase-3 in tumors to reduce tumor volume without overt toxicity. Thus, ST-11 represents the first member of a new class of brain-penetrant antitubulin therapeutic agents. Mol Cancer Ther; 15(9); 2018–29. ©2016 AACR.
  • Access State: Open Access